ClinicaliQ Trial Snapshot
- EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma — Recruiting • Phase III • Oncology • NCT06556563.
- Trial testing whether adding immunotherapy (pembrolizumab) to standard glioblastoma treatment improves survival compared to standard treatment alone.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS). Conditions: Glioblastoma Interventions: Optune® device, Temozolomide, Pembrolizumab, Placebo Lead Sponsor: NovoCure GmbH Planned Enrollment: 741 participants